Results 121 to 130 of about 37,863 (256)

Genetically engineered human cortical spheroid models of tuberous sclerosis. [PDF]

, 2018
Tuberous sclerosis complex (TSC) is a multisystem developmental disorder caused by mutations in the TSC1 or TSC2 genes, whose protein products are negative regulators of mechanistic target of rapamycin complex 1 signaling. Hallmark pathologies of TSC are
Bateup, Helen, Blair, John, Hockemeyer, Dirk   +2 more
core   +1 more source

Proteomics reveals three molecular subtypes of Alzheimer's disease with distinct progression patterns

Alzheimer's &Dementia, Volume 22, Issue 2, February 2026.
Abstract INTRODUCTION Alzheimer's disease (AD) shows marked molecular heterogeneity. Defining biological subtypes may refine diagnosis and treatment. METHODS We analyzed cerebrospinal fluid (CSF) proteomics and longitudinal data from 550 participants in the Alzheimer's Disease Neuroimaging Initiative with up to 16.5 years of follow‐up. We profiled 6361
Xiao‐He Hou, Wei Zhang, Kairan Kang, Yifei Jin, Peng Ren, Linbo Wang, Zeyu Li, Yuzhu Li, Jia You, Bei Zhang, Qing Ma, for the Alzheimer's Disease Neuroimaging Initiative, Fang Xie, Jin‐Tai Yu, Jian‐Feng Feng, Wei Cheng   +15 more
wiley   +1 more source

An Anoikis Resistance Phenotype Converged to Immune Dysfunction and Resistance to Immune Checkpoint Blockades in Gastric Cancer

Cancer Innovation, Volume 5, Issue 1, February 2026.
Gastric cancer (GC) has high global incidence and mortality, with most cases diagnosed at advanced stages. Immunotherapy, particularly immune checkpoint blockers (ICBs), has shown promise, but not all patients benefit. This study applied consensus clustering based on anoikis‐related genes (ANRGs) to classify GC into two subclusters.
Xing Cai, Jinru Yang, Fangyuan Zhang, Fuwang Xu, Yuan Fang, Zongbi Yi   +5 more
wiley   +1 more source

Progress in RNA‐Targeted Therapeutics for Human Diseases

MedComm, Volume 7, Issue 2, February 2026.
RNA‐targeted therapies are revolutionizing molecular medicine by transitioning from a “protein‐centric” focus to an “RNA‐regulatory network” approach. Leveraging RNA's diverse roles in gene regulation, signaling, and epigenetic modifications, advanced platforms such as ASOs, siRNA, miRNA, mRNA, aptamers, shRNA, and CRISPR/Cas systems are enabling ...
Wangzheqi Zhang, Aimin Jiang, Bin‐Kui Jia, Yuming Jin, Yinghu Chen, Zhaoyu Li, Yan Liao, Haoling Zhang, Zhiheng Lin, Xiao Fang, Linhui Wang   +10 more
wiley   +1 more source

mTORC1 hampers Hedgehog signaling inTsc2deficient cells [PDF]

Life Science Alliance
The mTORC1-complex is negatively regulated by TSC1 and TSC2. Activation of Hedgehog signaling is strictly dependent on communication between Smoothened and the Hedgehog-signaling effector and transcription factor, GLI2, in the primary cilium. Details about this communication are not known, and we wanted to explore this further.
Lasse Jonsgaard Larsen, Elsebet Østergaard, Lisbeth Birk Møller   +2 more
openaire   +3 more sources

Data from p53 Deletion or Hotspot Mutations Enhance mTORC1 Activity by Altering Lysosomal Dynamics of TSC2 and Rheb

, 2023
Stuti Agarwal, Catherine Bell, Shirley M. Taylor, Richard G. Moran   +3 more
openalex   +1 more source

Exceptional therapeutic benefit of imatinib in cKIT‐mutated mucosal melanoma followed by a KIT mutation loss

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Hannah Zillikens, Corinna Scheib, Vicky Peller, Christina Müller, Sebastian Bauer, Ina Pretzell, Klaus Griewank, Antje Sucker, Eva Hadaschik, Felicitas Guntrum, Sven Holger Baum, Alexander Roesch, Selma Ugurel, Dirk Schadendorf, Lisa Zimmer, Elisabeth Livingstone   +15 more
wiley   +1 more source

Molecular alterations in high‐grade neuroendocrine tumors of the small intestine

The Journal of Pathology, Volume 268, Issue 2, Page 215-226, February 2026.
Abstract High‐grade neuroendocrine tumors of the small intestine are separated into two groups: well‐differentiated neuroendocrine tumors (NETs, high‐grade) and poorly differentiated neuroendocrine carcinomas (NECs). They represent very rare entities, with few molecular data available, and are very challenging to treat.
Agathe Hercent, Julien Masliah‐Planchon, David Cohen, Remy Nicolle, Jean‐Yves Scoazec, Philippe Ruszniewski, Ivan Bièche, Louis de Mestier, Anne Couvelard, Jerome Cros   +9 more
wiley   +1 more source

Heterozygous Tsc2 (Tsc2+/–) mouse model to study induced renal cancer in response to ionizing radiation at low doses

Carcinogenesis, 2018
Abstract Kidneys are one of the main dose-limiting organs in radiotherapeutic procedures of lower abdomen. Likewise, the threat of exposure of radiosensitive organs such as kidneys in warfare or radiation accidents among military personal or due to terrorist activities in general public is of increasing concern.
Sureshkumar M A, Caroline R Delma, Krishnan Manickam, Sumathy Mohan, Samy L Habib, Mohan Natarajan   +5 more
openaire   +2 more sources

Comparison of three rapamycin dosing schedules in A/J Tsc2^+/- mice and improved survival with angiogenesis inhibitor or asparaginase treatment in mice with subcutaneous tuberous sclerosis related tumors

Journal of Translational Medicine, 2010
Background Tuberous Sclerosis Complex (TSC) is an autosomal dominant tumor disorder characterized by the growth of hamartomas in various organs including the kidney, brain, skin, lungs, and heart.
Dabora Sandra L, Nobil Alison, Woodrum Chelsey   +2 more
doaj   +1 more source